$CYRX
Cryoport, Inc. Stock $cyrx

$cyrx Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000114420413045750 Filed on August 14, 2013

Income Statement

Concept	2013 Q3	2013 Q2	2012 Q2
Revenue	$580.0K	$488.0K	$191.0K
YoY Change	147.86%	155.5%	59.17%
Cost Of Revenue	$507.7K	$433.3K	$353.6K
YoY Change	47.41%	22.54%	1.03%
Gross Profit	$72.00K	$55.00K	-$163.0K
YoY Change	-164.86%	-133.74%	-29.13%
Gross Profit Margin	12.41%	11.27%	-85.34%
Selling, General & Admin	$1.240M	$1.222M	$1.269M
YoY Change	-7.52%	-3.72%	-22.13%
% of Gross Profit	1722.8%	2221.95%
Research & Development	$118.4K	$92.64K	$109.0K
YoY Change	16.51%	-14.97%	8.95%
% of Gross Profit	164.49%	168.44%
Depreciation & Amortization	$61.82K	$89.44K	$95.03K
YoY Change	-33.31%	-5.88%	18.79%
% of Gross Profit	85.87%	162.62%
Operating Expenses	$1.359M	$1.315M	$1.378M
YoY Change	-5.83%	-4.61%	-20.33%
Operating Profit	-$1.287M	-$1.260M	-$1.541M
YoY Change	-17.18%	-18.23%	-21.38%
Interest Expense	$512.8K	$82.22K	$24.60K
YoY Change	4260.71%	234.24%	-127.33%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	-$5.264K
YoY Change	-100.0%	-100.0%
Pretax Income	-$14.96M	-$1.324M	-$1.546M
YoY Change	864.45%	-14.38%	-24.59%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$14.96M	-$1.324M	-$1.546M
YoY Change	864.54%	-14.36%	-24.59%
Net Earnings / Revenue	-2579.31%	-271.31%	-809.42%
Basic Earnings Per Share
Diluted Earnings Per Share	-$4.589M	-$416.4K	-$492.1K
COMMON SHARES
Basic Shares Outstanding	38.26M shares
Diluted Shares Outstanding	40.52M shares	39.03M shares	37.77M shares

Balance Sheet

Concept	2013 Q3	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$500.0K	$200.0K	$3.000M
YoY Change	-70.59%	-93.33%	-57.75%
Cash & Equivalents	$532.5K	$227.5K	$2.972M
Short-Term Investments
Other Short-Term Assets	$40.69K	$185.0K	$0.00
YoY Change			-100.0%
Inventory	$43.31K	$52.86K	$0.00
Prepaid Expenses
Receivables	$387.7K	$357.7K	$100.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.004M	$823.1K	$3.200M
YoY Change	-47.15%	-74.28%	-58.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$516.6K	$575.0K	$700.0K
YoY Change	-13.9%	-17.85%	0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$0.00
YoY Change
Total Long-Term Assets	$753.2K	$839.3K	$1.000M
YoY Change	-16.31%	-16.07%	0.0%
TOTAL ASSETS
Total Short-Term Assets	$1.004M	$823.1K	$3.200M
Total Long-Term Assets	$753.2K	$839.3K	$1.000M
Total Assets	$1.757M	$1.662M	$4.200M
YoY Change	-37.24%	-60.42%	-51.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$600.0K	$800.0K	$400.0K
YoY Change	20.0%	100.0%	0.0%
Accrued Expenses	$300.0K	$300.0K	$100.0K
YoY Change	200.0%	200.0%	-80.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$100.0K	$2.300M	$100.0K
YoY Change	0.0%	2200.0%	-95.0%
Total Short-Term Liabilities	$1.043M	$3.378M	$600.0K
YoY Change	48.94%	462.95%	-81.25%
LONG-TERM LIABILITIES
Long-Term Debt	$1.300M	$1.300M	$1.400M
YoY Change	0.0%	-7.14%	0.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$1.300M	$1.300M	$1.400M
YoY Change	0.0%	-7.14%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.043M	$3.378M	$600.0K
Total Long-Term Liabilities	$1.300M	$1.300M	$1.400M
Total Liabilities	$2.335M	$4.685M	$2.000M
YoY Change	11.2%	134.25%	-56.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$82.59M	-$67.63M
YoY Change
Common Stock	$82.02M	$64.61M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$577.9K	-$3.023M	$2.300M
YoY Change
Total Liabilities & Shareholders Equity	$1.757M	$1.662M	$4.200M
YoY Change	-37.24%	-60.42%	-51.72%

Cashflow Statement

Concept	2013 Q3	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$14.96M	-$1.324M	-$1.546M
YoY Change	864.54%	-14.36%	-24.59%
Depreciation, Depletion And Amortization	$61.82K	$89.44K	$95.03K
YoY Change	-33.31%	-5.88%	18.79%
Cash From Operating Activities	-$1.150M	-$1.171M	-$1.425M
YoY Change	-7.26%	-17.81%	-8.08%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	$131.3K	$43.87K
YoY Change	0.0%	199.19%	-162.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$10.00K	-$131.3K	-$43.87K
YoY Change	0.0%	199.19%	-37.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.450M	$966.7K	-$177.3K
YoY Change	-2171.43%	-645.28%	-70.94%
NET CHANGE
Cash From Operating Activities	-1.150M	-$1.171M	-$1.425M
Cash From Investing Activities	-10.00K	-$131.3K	-$43.87K
Cash From Financing Activities	1.450M	$966.7K	-$177.3K
Net Change In Cash	290.0K	-$335.6K	-$1.646M
YoY Change	-121.97%	-79.61%	-26.19%
FREE CASH FLOW
Cash From Operating Activities	-$1.150M	-$1.171M	-$1.425M
Capital Expenditures	-$10.00K	$131.3K	$43.87K
Free Cash Flow	-$1.140M	-$1.302M	-$1.469M
YoY Change	-7.32%	-11.33%	-0.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	357702	USD
CY2013Q2	dei	Document Type DocumentType	10-Q
CY2013Q2	dei	Amendment Flag AmendmentFlag	false
CY2013Q2	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
CY2013Q2	dei	Trading Symbol TradingSymbol	CYRX
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	38260628	shares
CY2013Q2	dei	Entity Registrant Name EntityRegistrantName	Cryoport, Inc.
CY2013Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001124524
CY2013Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2013Q2	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	106999	USD
CY2013Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	227530	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	563104	USD
CY2013Q1	us-gaap	Inventory Net InventoryNet	39212	USD
CY2013Q2	us-gaap	Other Assets Current OtherAssetsCurrent	185010	USD
CY2013Q1	us-gaap	Other Assets Current OtherAssetsCurrent	138892	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	823106	USD
CY2013Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	823190	USD
CY2013Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	272263	USD
CY2013Q1	us-gaap	Assets Assets	1755797	USD
CY2013Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	217097	USD
CY2013Q2	us-gaap	Inventory Net InventoryNet	52864	USD
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	37761	USD
CY2013Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	64574114	USD
CY2013Q2	us-gaap	Sales Revenue Net SalesRevenueNet	487963	USD
CY2012Q2	us-gaap	Sales Revenue Net SalesRevenueNet	191299	USD
CY2013Q2	us-gaap	Cost Of Revenue CostOfRevenue	433321	USD
CY2013Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2013Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2497408	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	505485	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	244540	USD
CY2013Q2	us-gaap	Assets Assets	1662414	USD
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q2	us-gaap	Liabilities Liabilities	4685024	USD
CY2012Q2	us-gaap	Cost Of Revenue CostOfRevenue	353618	USD
CY2013Q2	us-gaap	Gross Profit GrossProfit	54642	USD
CY2012Q2	us-gaap	Gross Profit GrossProfit	-162319	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1662414	USD
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38062826	shares
CY2013Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	89443	USD
CY2012Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	30894	USD
CY2012Q2	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-1483	USD
CY2012Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	43871	USD
CY2013Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	10767	USD
CY2013Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	140605	USD
CY2012Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1358	USD
CY2013Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	13652	USD
CY2012Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-4248	USD
CY2012Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-28385	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	575024	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	958305	USD
CY2013Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	858709	USD
CY2013Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	280445	USD
CY2013Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	217432	USD
CY2013Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	2175980	USD
CY2013Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1304419	USD
CY2013Q2	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	96000	USD
CY2013Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	96000	USD
CY2013Q2	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	2091	USD
CY2013Q1	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	20848	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3377706	USD
CY2013Q2	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	1307318	USD
CY2013Q1	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	1321664	USD
CY2013Q1	us-gaap	Liabilities Liabilities	3819072	USD
CY2013Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	38261	USD
CY2013Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	64210412	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-67634985	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66311448	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	-3022610	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	-2063275	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1755797	USD
CY2013Q2	cyrx	Depositsandotherassets Depositsandotherassets	19744	USD
CY2013Q1	cyrx	Depositsandotherassets Depositsandotherassets	19744	USD
CY2013Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1222074	USD
CY2012Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1269272	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	92643	USD
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	108952	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	1314717	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	1378224	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1260075	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1540543	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	82219	USD
CY2012Q2	us-gaap	Interest Expense InterestExpense	24599	USD
CY2013Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	18757	USD
CY2012Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	19335	USD
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-63462	USD
CY2012Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5264	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1323537	USD
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1545807	USD
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2012Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-1323537	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-1545807	USD
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37760628	shares
CY2012Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	95029	USD
CY2013Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	50883	USD
CY2012Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	8843	USD
CY2013Q2	cyrx	Fair Value Of Stock Options And Warrants Issued To Consultants Employees And Directors FairValueOfStockOptionsAndWarrantsIssuedToConsultantsEmployeesAndDirectors	-157203	USD
CY2012Q2	cyrx	Fair Value Of Stock Options And Warrants Issued To Consultants Employees And Directors FairValueOfStockOptionsAndWarrantsIssuedToConsultantsEmployeesAndDirectors	-80836	USD
CY2013Q2	us-gaap	Unrealized Gain Loss On Derivatives And Commodity Contracts UnrealizedGainLossOnDerivativesAndCommodityContracts	18757	USD
CY2012Q2	us-gaap	Unrealized Gain Loss On Derivatives And Commodity Contracts UnrealizedGainLossOnDerivativesAndCommodityContracts	19335	USD
CY2013Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-54278	USD
CY2013Q2	cyrx	Increase Decrease In Accrued Compensation And Related Expense IncreaseDecreaseInAccruedCompensationAndRelatedExpense	-63013	USD
CY2012Q2	cyrx	Increase Decrease In Accrued Compensation And Related Expense IncreaseDecreaseInAccruedCompensationAndRelatedExpense	107785	USD
CY2013Q2	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	30063	USD
CY2013Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1170991	USD
CY2012Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1424817	USD
CY2013Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	131259	USD
CY2013Q2	cyrx	Release Of Restricted Cash For Repayment Of Convertible Debentures Payable ReleaseOfRestrictedCashForRepaymentOfConvertibleDebenturesPayable	0	USD
CY2012Q2	cyrx	Release Of Restricted Cash For Repayment Of Convertible Debentures Payable ReleaseOfRestrictedCashForRepaymentOfConvertibleDebenturesPayable	251368	USD
CY2013Q2	cyrx	Deferred Financing Costs In Connection With Convertible Debt Payable Included In Accounts Payable DeferredFinancingCostsInConnectionWithConvertibleDebtPayableIncludedInAccountsPayable	70234	USD
CY2012Q2	cyrx	Deferred Financing Costs In Connection With Convertible Debt Payable Included In Accounts Payable DeferredFinancingCostsInConnectionWithConvertibleDebtPayableIncludedInAccountsPayable	0	USD
CY2013Q2	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	106999	USD
CY2012Q2	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	0	USD
CY2013Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-131259	USD
CY2012Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-43871	USD
CY2013Q2	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	958151	USD
CY2012Q2	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2013Q2	cyrx	Repayments Of Convertible Debentures Payable RepaymentsOfConvertibleDebenturesPayable	0	USD
CY2012Q2	cyrx	Repayments Of Convertible Debentures Payable RepaymentsOfConvertibleDebenturesPayable	82800	USD
CY2013Q2	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	67475	USD
CY2012Q2	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	78480	USD
CY2013Q2	cyrx	Repayments Of Related Party Notes Payable RepaymentsOfRelatedPartyNotesPayable	24000	USD
CY2012Q2	cyrx	Repayments Of Related Party Notes Payable RepaymentsOfRelatedPartyNotesPayable	16000	USD
CY2013Q2	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	100000	USD
CY2012Q2	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
CY2013Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	966676	USD
CY2012Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-177280	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-335574	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1645968	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4617535	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2971567	USD
CY2013Q2	us-gaap	Interest Paid InterestPaid	0	USD
CY2012Q2	us-gaap	Interest Paid InterestPaid	12577	USD
CY2013Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	9100	USD
CY2013Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	8700	USD
CY2013Q2	cyrx	Maturity Period Of Highly Liquid Investments MaturityPeriodOfHighlyLiquidInvestments	P90D
CY2013Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
CY2013Q1	cyrx	Cash Exceeds Fdic Insurance Limits CashExceedsFdicInsuranceLimits	214000	USD
CY2013Q2	cyrx	Foreign Sales Revenue Net ForeignSalesRevenueNet	144000	USD
CY2012Q2	cyrx	Foreign Sales Revenue Net ForeignSalesRevenueNet	81000	USD
CY2013Q2	cyrx	Percentage Of Foreign Sales Revenue PercentageOfForeignSalesRevenue	0.29	pure
CY2012Q2	cyrx	Percentage Of Foreign Sales Revenue PercentageOfForeignSalesRevenue	0.42	pure
CY2013Q2	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	0.3	pure
CY2012Q2	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	0.16	pure
CY2013Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	39661	USD
CY2013Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	28533	USD
CY2013Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	13203	USD
CY2013Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10679	USD
CY2013Q2	cyrx	Property Plant And Equipment Percentage Of Specific Assets PropertyPlantAndEquipmentPercentageOfSpecificAssets	0.9	pure
CY2013Q1	cyrx	Property Plant And Equipment Percentage Of Specific Assets PropertyPlantAndEquipmentPercentageOfSpecificAssets	0.87	pure
CY2013Q2	us-gaap	Depreciation Depreciation	61720	USD
CY2012Q2	us-gaap	Depreciation Depreciation	66841	USD
CY2013Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	27723	USD
CY2012Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	28188	USD
CY2013Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39034000	shares
CY2012Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37772000	shares
CY2013Q2	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P3Y
CY2013Q2	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in; FONT: 10pt Times New Roman, Times, Serif"> <strong style="TEXT-INDENT: 0in; MARGIN: 0in"><em>Concentrations of Credit Risk</em></strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company maintains its cash accounts in financial institutions. Accounts at these institutions are insured by the Federal Deposit Insurance Corporation (“FDIC”) with basic deposit coverage limits up to $<font style=" FONT-SIZE: 10pt">250,000</font> per owner. At June 30, 2013 and March 31, 2013, the Company had <font style=" FONT-SIZE: 10pt">$0 and</font> approximately $<font style=" FONT-SIZE: 10pt">214,000</font>, respectively, which exceeded the FDIC insurance limit, of cash balances. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure.</div> </div>
CY2013Q2	us-gaap	Use Of Estimates UseOfEstimates	<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in; FONT: 10pt Times New Roman, Times, Serif"> <strong style="TEXT-INDENT: 0in; MARGIN: 0in"><em>Use of Estimates</em></strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include allowances for doubtful accounts and sales returns, recoverability of long-lived assets, deferred taxes and their accompanying valuations, valuation of derivative liabilities and valuation of common stock, warrants and stock options issued for products or services.<font size="2"> </font></div> </div>
CY2013Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	20848	USD
CY2012Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	37334	USD
CY2013Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-18757	USD
CY2012Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-19335	USD
CY2013Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2091	USD
CY2012Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	17999	USD
CY2013Q2	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	627500	USD
CY2013Q1	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	651500	USD
CY2006Q2	cyrx	Aggregate Monthly Principal Payment AggregateMonthlyPrincipalPayment	2500	USD
CY2013Q2	cyrx	Increased In Monthly Principal Payment IncreasedInMonthlyPrincipalPayment	2500	USD
CY2013Q2	cyrx	Maximum Amount Of Aggregate Monthly Principal Payment MaximumAmountOfAggregateMonthlyPrincipalPayment	10000	USD
CY2013Q2	cyrx	Aggregate Principal Payment AggregatePrincipalPayment	8000	USD
CY2013Q2	cyrx	Maturity Period Of Remaining Unpaid Principal And Accrued Interest MaturityPeriodOfRemainingUnpaidPrincipalAndAccruedInterest	2015-03-01
CY2013Q2	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	9654	USD
CY2012Q2	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	11094	USD
CY2013Q2	cyrx	Accrued Interest Related Party AccruedInterestRelatedParty	775818	USD
CY2013Q1	cyrx	Accrued Interest Related Party AccruedInterestRelatedParty	766164	USD
CY2013Q2	us-gaap	Related Party Transaction Rate RelatedPartyTransactionRate	0.06	pure
CY2013Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2012Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	3091	USD
CY2013Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2252651	USD
CY2013Q2	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
CY2013	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38260628	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38260628	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37760628	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37760628	shares
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2013Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q2	cyrx	Lease Payment Per Month LeasePaymentPerMonth	9250	USD
CY2012Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	58000	USD
CY2013Q2	cyrx	Minimum Amount Of Additional Compensation MinimumAmountOfAdditionalCompensation	2000000	USD
CY2012Q2	cyrx	Consulting Service Fee ConsultingServiceFee	100170	USD
CY2013Q2	cyrx	Number Of Installment To Discharge Additional Compensation NumberOfInstallmentToDischargeAdditionalCompensation	3	pure
CY2013Q2	cyrx	Period For Completion Of Agreement PeriodForCompletionOfAgreement	P1Y
CY2013Q2	us-gaap	Guarantee Obligations Current Carrying Value GuaranteeObligationsCurrentCarryingValue	0	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.35	pure
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.27	pure
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0169	pure
CY2013Q2	cyrx	Additional Information For Additional Compensation AdditionalInformationForAdditionalCompensation	additional compensation shall not be less than $2 million plus two times the "cost of work"
CY2013Q2	cyrx	Automatically Renewal Period AutomaticallyRenewalPeriod	P1Y
CY2013Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	48000	USD
CY2013Q2	cyrx	Consulting Service Fee ConsultingServiceFee	88311	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0019	pure
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.59	pure
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.24	pure
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0222	pure
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0083	pure
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y2M26D
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y4D
CY2012Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	30000	shares
CY2012Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	0.50
CY2012Q2	cyrx	Term Of Services Provided By Consultant TermOfServicesProvidedByConsultant	P2Y
CY2011Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	155844	shares
CY2011Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	0.77
CY2011Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2500	shares
CY2013Q2	cyrx	Class Of Warrant Or Right Expense ClassOfWarrantOrRightExpense	277	USD
CY2012Q2	cyrx	Class Of Warrant Or Right Expense ClassOfWarrantOrRightExpense	277	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	1200000	shares
CY2012Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3000000	shares
CY2011Q4	cyrx	Term Of Services Provided By Consultant TermOfServicesProvidedByConsultant	P5Y
CY2011Q2	cyrx	Term Of Services Provided By Consultant TermOfServicesProvidedByConsultant	P3Y
CY2011Q2	cyrx	Term Of Warrants TermOfWarrants	P5Y
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	614794	shares
CY2013Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2027102	USD
CY2013Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y9M22D
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	500000	shares
CY2013Q2	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	100000	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.27
CY2012Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2013Q2	cyrx	Stock Issued During Period Shares Stock Option Exercised StockIssuedDuringPeriodSharesStockOptionExercised	500000	shares
CY2013Q2	invest	Investment Options Exercise Price InvestmentOptionsExercisePrice	0.2
CY2013Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	100000	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12260888	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4185358	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.93
CY2013Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.20
CY2013Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.07
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	148500	USD
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	145833	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.24
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.47
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.56
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7352291	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5408597	shares
CY2013Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	500000	shares

Files In Submission

Name	View Source	Status
0001144204-13-045750-index-headers.html	Edgar Link	pending
0001144204-13-045750-index.html	Edgar Link	pending
0001144204-13-045750.txt	Edgar Link	pending
0001144204-13-045750-xbrl.zip	Edgar Link	pending
cyrx-20130630.xml	Edgar Link	completed
cyrx-20130630.xsd	Edgar Link	pending
cyrx-20130630_cal.xml	Edgar Link	unprocessable
cyrx-20130630_def.xml	Edgar Link	unprocessable
cyrx-20130630_lab.xml	Edgar Link	unprocessable
cyrx-20130630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
image_002.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v352065_10q.htm	Edgar Link	pending
v352065_ex31-1.htm	Edgar Link	pending
v352065_ex31-2.htm	Edgar Link	pending
v352065_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CYRX
Cryoport, Inc. Stock $cyrx

2013 Q3 Form 10-Q Financial Statement

#000114420413045750 Filed on August 14, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYRX Cryoport, Inc. Stock $cyrx

2013 Q3 Form 10-Q Financial Statement

#000114420413045750 Filed on August 14, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYRX
Cryoport, Inc. Stock $cyrx